Filing Flows › Aligos Therapeutics (ALGS) › Q3 2026 › vs Q3 2025
Aligos Therapeutics (ALGS) Q3 2026 vs Q3 2025 (year over year)
Aligos Therapeutics's revenue rose $2.1M (+282%) from $741K in Q3 2025 to $2.8M in Q3 2026.
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.8M | $741K | $2.1M | +282% |
| Other income, net | $356K | −$3.1M | $3.5M | — |
| Net loss | $21.9M | $31.5M | −$9.7M | -31% |
| Costs & expenses | $25.0M | $32.3M | −$7.2M | -22% |
| Operating costs | $24.7M | $29.1M | −$4.4M | -15% |
| Income tax | $326K | $56K | $270K | +482% |
| Research & development | $18.9M | $23.9M | −$5.0M | -21% |
| General & admin | $5.9M | $5.2M | $702K | +14% |
| Operating cash sources | $23.3M | $7.2M | $16.1M | +224% |
| Depreciation | $300K | $200K | $100K | +50% |
| Share-based compensation | $1.3M | $1.5M | −$185K | -13% |
| Working capital & other | $21.7M | $5.5M | $16.2M | +293% |
| Net loss absorbed | $21.9M | $31.5M | −$9.7M | -31% |
| Operating cash flow | $1.5M | −$24.3M | $25.8M | — |
Questions
How much did Aligos Therapeutics's revenue grow year over year in Q3 2026?
Aligos Therapeutics's revenue rose $2.1M (+282%) from $741K in Q3 2025 to $2.8M in Q3 2026.